BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

13 1 2025 09:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

07 1 2025 09:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

17 12 2024 08:10:00 提供 Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

16 12 2024 18:15:01 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

12 12 2024 17:02:21 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

09 12 2024 16:01:00 提供 Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

06 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

02 12 2024 16:05:00 提供 Nasdaq GlobeNewswire

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

18 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 11 2024 16:05:51 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

30 10 2024 16:00:48 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

29 10 2024 16:46:08 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

21 10 2024 09:00:29 提供 Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

15 10 2024 16:05:19 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

07 10 2024 09:00:41 提供 Nasdaq GlobeNewswire

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

01 10 2024 09:00:01 提供 Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

26 9 2024 14:00:57 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 8 2024 16:05:20 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

31 7 2024 16:05:22 提供 Nasdaq GlobeNewswire